Genmab Announces Financial Results for the First Half of 2023
August 3, 2023 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30,…
Risk Management
Genmab Updates 2023 Financial Guidance
Company Announcement COPENHAGEN, Denmark; July 28, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its…
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Company Announcement The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 phase…
What to Look for in a Modern Insider Risk Solution
Insider threat can be described as the potential of an employee to utilize their authorised…
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and…
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
Media Release COPENHAGEN, Denmark; June 22, 2023 – Genmab A/S (Nasdaq: GMAB) today announced that…
Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)
— VASCEPA® Approved in KSA To Reduce the Risk of Cardiovascular (CV) Events as an…
SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance,…
SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance,…
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
Media Release COPENHAGEN, Denmark; June 9, 2023, at 9:00am CEST Results from phase 1/2 EPCORE™…
Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
Media Release COPENHAGEN, Denmark; June 6, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its…
Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
Media Release COPENHAGEN, Denmark; June 6, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its…
Culture Biosciences Establishes Advisory Board of Biotech and Biopharma Executives to Guide the Corporate Strategy and Accelerate Growth
Seasoned sector leaders will advise Culture’s leadership in customer intelligence and innovation SAN FRANCISCO, June…
Culture Biosciences Establishes Advisory Board of Biotech and Biopharma Executives to Guide the Corporate Strategy and Accelerate Growth
Seasoned sector leaders will advise Culture’s leadership in customer intelligence and innovation SAN FRANCISCO, June…
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
Media Release COPENHAGEN, Denmark; May 25, 2023 Oral presentations will highlight epcoritamab–bysp in combination with…
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
Media Release COPENHAGEN, Denmark; May 25, 2023 Oral presentations will highlight epcoritamab–bysp in combination with…
BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE…
Genmab Announces Financial Results for the First Quarter of 2023
May 10, 2023 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023…
Genmab Announces Financial Results for the First Quarter of 2023
May 10, 2023 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023…
Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
Company Announcement COPENHAGEN, Denmark; April 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its…